CAU Scholar's Space: Kim, Hee Jun

Detailed Information

Kim, Hee Jun (김희준)

의과대학 (의학부(임상-서울))

Research Area

Tel 031-670-3159
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Breast cancer:6||breast cancer:4||Chemotherapy:2||Menopause:2||mobile phone:2||Survival:2||Quality of life:2||chemotherapy:2||Irinotecan:2||DNA damage response:2||Oxaliplatin:2||Brain metastasis:2||ATR inhibitor:2||Anxiety:2||Carryover effect:1||Chemotherapyinduced neutropenia:1||Chronic myelomonocytic leukemia (CMML):1||Cisplatinunfit:1||Clear cell adenocarcinoma:1||Clinical trial:1||Cognitive behavioral therapy:1||Cohort study:1||Congestive heart failure:1||Cyclooxygenase 2:1||Cyclophosphamide:1||Default mode network:1||Depression:1||Digital health:1||Duodenal Polyp:1||Epidemiology:1||Exercise:1||Exercise therapy:1||Fluorouracil:1||Gall bladder (GB):1||Gastric cancer:1||Gemcitabine:1||Hepatocellular carcinoma:1||Homologous recombination:1||IFNγ:1||Immunohistochemistry:1||Incidence:1||Insula:1||Isolated LCDD:1||Kidney:1||Korea:1||Korea National Health and Nutrition Examination Survey:1||Korean:1||Light Chain Deposition Disease (LCDD):1||Lung cancer:1||Lymphatic Metastasis:1||MLH1:1||MSH2:1||Male:1||Mandible:1||Menopausal symptoms:1||Mental Health Status:1||Metabolic equivalent:1||Metastatic breast cancer:1||Methotrexate:1||Mobile applications:1||Neutropenia:1||Occult Primary Neoplasm:1||Olaparib:1||Ovarian epithelial carcinoma:1||Overall survival:1||Palliative care:1||Pegteograstim:1||Pegylated GCSF:1||Perimenopause:1||Phase II:1||Physical Activity Intensity:1||Physical activity:1||Practice guideline:1||Prediction:1||Prognosis:1||Prognostic biomarker:1||Prognostic model:1||Progressionfree survival:1||Prophylaxis:1||Prostate neoplasms:1||RNA stability:1||Risk factor:1||Risk reduction behaviour:1||S1:1||Salience network:1||Secondary prevention:1||Serious game:1||Smad3:1||Stroke:1||Synovial sarcoma:1||TDP1:1||TGFβ1:1||TNFα:1||TOP1 activity:1||Terminal cancer:1||Terminally ill:1||Transforming growth factor beta:1||Tristetraprolin:1||Tumor molecular subtype:1||Ureteral stump:1||Urothelial cancer:1||Whole brain radiotherapy:1||Wholebrain radiotherapy:1||air pollution:1||autologous stem cell transplantation:1||bladder cancer:1||blood pressure:1||breast neoplasm:1||capecitabine:1||cardiac tamponade:1||cardiovascular disease risk factors:1||cardiovascular risk factors:1||dMMR:1||decitabine:1||epidemiology:1||fasting glucose:1||health education:1||homologous recombination:1||lipid profiles:1||lymph node:1||mHealth:1||mobile health:1||neoadjuvant chemotherapy:1||neutrophiltolymphocyte ratio:1||palbociclib:1||particulate matter:1||patientreported outcome measures:1||platelettoymphocyte ratio:1||premenopause:1||primary NK/Tcell lymphoma:1||primary effusion lymphoma:1||primary effusion lymphomalike lymphoma:1||psychological adjustments:1||quality of life:1||radical cystectomy:1||secondhand smoke exposure:1||selfefficacy:1||selfreport questionnaires:1||side effects:1||single nucleotide polymorphism:1||spine:1||sudden hearing loss (SHL):1||ABCB1 Gene:1||urine cotinine:1||AKI:1||Acute kidney injury:1||Adjuvant chemotherapy:1||Atrial fibrillation:1||Axilla:1||Bcell lymphoblastic lymphoma (BLBL):1||Braindirected treatment:1||Breast Cancer:1||Breast Neoplasm:1||Breast neoplasms:1||C3435T:1||Capecitabine:1||Carboplatin:1||

RSS_1.0 RSS_2.0 ATOM_1.0

84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE